Epidermolysis Bullosa Clinical Trial
Official title:
Randomised Double Blind Crossover Placebo Controlled Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa
Epidermolysis Bullosa(EB) is an inherited bullous disease. Tetracycline is believed to have anti inflammatory properties. 20 patients with EB older than 13 years will be treated for 4 months with tetracycline or placebo. After one month of wash out they will be treated for additional 4 m with placebo or tetracycline. The patients will be examined each month to estimate bulla formation,rate of healing .
Epidermolysis Bullosa(EB) is an inherited bullous disease. Tetracycline is believed to have anti inflammatory properties. 20 patients with EB older than 13 years will be treated for 4 months with tetracycline or placebo. After one month of wash out they will be treated for additional 4 m with placebo or tetracycline. The patients will be examined each month to estimate bulla formation,rate of healing . ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00380640 -
The Efficacy of Trimethoprim in Wound Healing of Patients With Epidermolysis Bullosa
|
Phase 2 | |
| Completed |
NCT00004761 -
Establishment of the National Epidermolysis Bullosa Registry
|
N/A | |
| Completed |
NCT01263379 -
Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa
|
Phase 1/Phase 2 | |
| Completed |
NCT01716169 -
Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care
|
N/A | |
| Withdrawn |
NCT01454687 -
Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes
|
N/A | |
| Completed |
NCT00014729 -
Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa
|
Phase 1 | |
| Recruiting |
NCT05838092 -
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)
|
Phase 3 | |
| Recruiting |
NCT03269474 -
Computational Drug Repurposing for All EBS Cases
|
||
| Completed |
NCT03068780 -
Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa
|
Phase 3 | |
| Terminated |
NCT02090283 -
Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
|
Phase 2 | |
| Completed |
NCT02582775 -
MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
|
Phase 2 | |
| Recruiting |
NCT04213703 -
A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
|
||
| Completed |
NCT02384460 -
ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
|
Phase 3 | |
| Terminated |
NCT02670330 -
Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa
|
Phase 3 | |
| Terminated |
NCT01619670 -
A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa
|
Phase 4 | |
| Recruiting |
NCT01340235 -
Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin
|
Phase 3 | |
| Completed |
NCT02014376 -
Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
|
Phase 2 | |
| Completed |
NCT04217538 -
Observational Study of a Cohort of Patients With Hereditary Epidermolysis Bullosa
|
||
| Completed |
NCT03942250 -
Uses of Irradiated Human Amniotic Membrane in the Treatment of Dystrophic Epidermolysis Bullosa Patients
|
N/A | |
| Completed |
NCT01033552 -
Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs
|
Phase 1/Phase 2 |